ANDRAS HECZEY to Child
This is a "connection" page, showing publications ANDRAS HECZEY has written about Child.
Connection Strength
0.435
-
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nat Med. 2023 Jun; 29(6):1379-1388.
Score: 0.052
-
Incidence and 5-year survival of children and adolescents with hepatoblastoma in the United States. Pediatr Blood Cancer. 2022 10; 69(10):e29763.
Score: 0.048
-
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis. Nat Med. 2020 11; 26(11):1686-1690.
Score: 0.043
-
50 Years Ago in The Journal of Pediatrics: Survival of Children with Neuroblastoma Treated with Combination Chemotherapy. J Pediatr. 2018 12; 203:233.
Score: 0.038
-
Cost-effectiveness and Improved Parent and Provider Satisfaction With Outpatient Management of Pediatric Oncology Patients, With Low-risk Fever and Neutropenia. J Pediatr Hematol Oncol. 2018 10; 40(7):e415-e420.
Score: 0.037
-
CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. Mol Ther. 2017 09 06; 25(9):2214-2224.
Score: 0.034
-
IMAGES IN CLINICAL MEDICINE. Osteopetrosis and Erlenmeyer-Flask Deformity. N Engl J Med. 2015 Sep 03; 373(10):e12.
Score: 0.030
-
Advances in chimeric antigen receptor immunotherapy for neuroblastoma. Discov Med. 2013 Dec; 16(90):287-94.
Score: 0.027
-
Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood. 2022 07 07; 140(1):16-24.
Score: 0.012
-
Hepatoblastomas with carcinoma features represent a biological spectrum of aggressive neoplasms in children and young adults. J Hepatol. 2022 10; 77(4):1026-1037.
Score: 0.012
-
Transarterial Radioembolization Treatment as a Bridge to Surgical Resection in Pediatric Hepatocellular Carcinoma. J Pediatr Hematol Oncol. 2021 Nov 01; 43(8):e1181-e1185.
Score: 0.012
-
Integration of a dedicated management protocol in the care of pediatric liver cancer: From specialized providers to complication reduction. J Pediatr Surg. 2022 Aug; 57(8):1544-1553.
Score: 0.011
-
Is high-risk neuroblastoma induction chemotherapy possible without G-CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors. Pediatr Blood Cancer. 2020 10; 67(10):e28417.
Score: 0.011
-
Agenesis of the corpus callosum and hepatoblastoma. Am J Med Genet A. 2020 01; 182(1):224-228.
Score: 0.010
-
Predisposing Conditions to Pediatric Hepatocellular Carcinoma and Association With Outcomes: Single-center Experience. J Pediatr Gastroenterol Nutr. 2019 05; 68(5):695-699.
Score: 0.010
-
Characterization of pediatric hepatocellular carcinoma reveals genomic heterogeneity and diverse signaling pathway activation. Pediatr Blood Cancer. 2019 07; 66(7):e27745.
Score: 0.010
-
Cholangiocarcinoma Among Children and Adolescents: A Review of the Literature and Surveillance, Epidemiology, and End Results Program Database Analysis. J Pediatr Gastroenterol Nutr. 2018 01; 66(1):e12-e18.
Score: 0.009
-
Vascular invasion is a prognostic indicator in hepatoblastoma. J Pediatr Surg. 2017 Jun; 52(6):956-961.
Score: 0.008
-
Undifferentiated Embryonal Sarcoma of the Liver (UESL): A Single-Center Experience and Review of the Literature. J Pediatr Hematol Oncol. 2016 05; 38(4):261-8.
Score: 0.008
-
Health disparities are important determinants of outcome for children with solid tumor malignancies. J Pediatr Surg. 2015 Jan; 50(1):161-6.
Score: 0.007
-
IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity. J Clin Invest. 2012 Jun; 122(6):2221-33.
Score: 0.006